The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for Kyinsu (insulin icodec + semaglutide, IcoSema) intended… read more.
A new analysis led by researchers at the Johns Hopkins Bloomberg School of Public Health finds that out-of-pockets caps on insulin for Medicare Part D beneficiaries have reined… read more.
Abbott announced results from the FreeDM2 randomized controlled trial (RCT) showing that people using FreeStyle Libre continuous glucose monitoring (CGM) technology had better glucose outcomes than those using… read more.
A one-size-fits-all approach to prediabetes treatment may miss the opportunity to implement an early, more intensive, tailored prevention approach for those with the highest risk of developing Type… read more.
Eli Lilly and Company announced that access to self-pay pricing on the new Zepbound (tirzepatide) KwikPen for single-patient use will be available at LillyDirect and major pharmacies nationwide,… read more.
Researchers report that people with type 1 diabetes are nearly three times as likely to develop dementia compared to those without type 1 diabetes. The findings appeared in… read more.
Glucagon-like peptide-1 (GLP-1) receptor agonists used to treat type 2 diabetes and obesity may also help to lower the risk of addiction to a range of substances including… read more.
To be healthy, conventional wisdom tells us to exercise and limit fatty foods. Exercise helps us lose weight and build muscle. It makes our hearts stronger and boosts… read more.
Sequel Med Tech, LLC, a company developing transformative drug delivery technologies, and Senseonics Holdings, Inc., a medical technology company focused on long-term, implantable Continuous Glucose Monitoring (CGM) systems… read more.
The FDA has accepted for priority review the supplemental biologic license application (sBLA) for Tzield (teplizumab-mzwv) to expand the current age indication from eight years and above, to… read more.
Medtronic announced significant U.S. milestones that expand access, choice, and flexibility for people living with type 1 and insulin‑requiring type 2 diabetes. These milestones include FDA clearance for… read more.
Soleno Therapeutics Inc. announced a publication in the peer-reviewed Journal of Clinical Endocrinology and Metabolism (JCEM). The paper, titled, “Diazoxide Choline Extended-Release Tablets in Prader-Willi Syndrome: A Randomized,… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
